Please select the option that best describes you:

Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?  

Assume life expectancy > 10 years and compliance with adjuvant/outback Herceptin



Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more